Journal Mobile Options
Table of Contents
Vol. 63, No. 4, 2002
Issue release date: November 2002
Oncology 2002;63:317–332
(DOI:10.1159/000066230)

The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications

Moschos S.J. · Mantzoros C.S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Insulin-like growth factors (IGFs) are important mediators of growth, development, and survival, are synthesized by almost any tissue in the body, and their action is modulated by a complex network of molecules, including binding proteins, proteases and receptors, which all comprise the IGF system. Evidence from in vitro and animal studies suggests that overexpression of IGFs by cancer cells and/or the nearby stroma as well as the type IGF-I receptor by the cancer cells may play a significant role in establishing a transformed phenotype in an increasing number of malignancies. More specifically, IGFs may promote cell cycle progression and inhibition of apoptosis either by directly associating with other growth factors or indirectly by interacting with other molecular systems which have an established role in carcinogenesis and cancer promotion, such as the steroid hormones and integrins. In addition, a growing number of epidemiologic studies suggest that increased serum levels of IGFs and/or altered levels of their binding proteins are associated with increased risk for developing several malignancies. These data indicate that IGF dysregulation should now be considered as an important independent factor for cancer risk, and a potential target for novel antineoplastic therapies and/or preventative strategies in high-risk groups.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Holly JM, Wass JA: Insulin-like growth factors; autocrine, paracrine or endocrine? New perspectives of the somatomedin hypothesis in the light of recent developments. J Endocrinol 1989;122:611–618.
  2. Stewart CE, Rotwein P: Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors. Physiol Rev 1996;76:1005–1026.
  3. D’Ercole AJ, Stiles AD, Underwood LE: Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984;81:935–939.
  4. Rosen CJ: Serum insulin-like growth factors and insulin-like growth factor-binding proteins: Clinical implications. Clin Chem 1999;45:1384–1390.
  5. Schwander JC, Hauri C, Zapf J, Froesch ER: Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: Dependence on growth hormone status. Endocrinology 1983;113:297–305.
  6. Tannenbaum GS, Guyda HJ, Posner BI: Insulin-like growth factors: A role in growth hormone negative feedback and body weight regulation via brain. Science 1983;220:77–79.
  7. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472–1489.
  8. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80–101.
  9. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C: Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J Clin Oncol 1999;17:813–817.
  10. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS: Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 1999;17:3291–3298.
  11. Allen NE, Appleby PN, Davey GK, Key TJ: Hormones and diet: Low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br J Cancer 2000;83:95–97.
  12. Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA: IGF-I is required for normal embryonic growth in mice. Genes Dev 1993;7:2609–2617.
  13. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999;96:7088–7092.
  14. O’Dell SD, Day IN: Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 1998;30:767–771.
  15. Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73–82.
  16. Rechler MM, Brown AL: Insulin-like growth factor binding proteins: Gene structure and expression. Growth Regul 1992;2:55–68.
  17. Frystyk J, Ivarsen P, Skjaerbaek C, Flyvbjerg A, Pedersen EB, Orskov H: Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999;56:2076–2084.
  18. Mauras N, Quarmby V, Bloedow DC: Pharmacokinetics of insulin-like growth factor I in hypopituitarism: Correlation with binding proteins. Am J Physiol 1999;277:E579–E584.
  19. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA: Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res 1999;31:192–202.
  20. Rajah R, Khare A, Lee PD, Cohen P: Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 1999;163:487–494.
  21. Zapf J: Physiological role of the insulin-like growth factor binding proteins. Eur J Endocrinol 1995;132:645–654.
  22. Baxter RC: Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab 1988;67:265–272.
  23. Boisclair YR, Hurst KR, Ueki I, Tremblay ML, Ooi GT: Regulation and role of the acid-labile subunit of the 150-kilodalton insulin-like growth factor complex in the mouse. Pediatr Nephrol 2000;14:562–566.
  24. Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions. Endocr Rev 1997;18:801–831.
  25. Arai T, Busby W Jr, Clemmons DR: Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996;137:4571–4575.
  26. Delbe J, Blat C, Desauty G, Harel L: Presence of IDF45 (mIGFBP-3) binding sites on chick embryo fibroblasts. Biochem Biophys Res Commun 1991;179:495–501.
  27. Conover CA, Clarkson JT, Bale LK: Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action. Endocrinology 1996;137:2286–2292.
  28. Conover CA, Bale LK, Durham SK, Powell DR: Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity. Endocrinology 2000;141:3098–3103.
  29. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P: The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 1995;9:361–367.
  30. Butt AJ, Firth SM, King MA, Baxter RC: Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000;275:39174–39181.
  31. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, Paraskeva C: Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 2000;60:22–27.
  32. Mira E, Manes S, Lacalle RA, Marquez G, Martinez AC: Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999;140:1657–1664.
  33. Leal SM, Liu Q, Huang SS, Huang JS: The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997;272:20572–20576.
  34. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y: Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999;140:1319–1328.
  35. Schneider MR, Lahm H, Wu M, Hoeflich A, Wolf E: Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J 2000;14:629–640.
  36. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P: Insulin-like growth factor binding protein proteases: Functional regulators of cell growth. Prog Growth Factor Res 1996;6:273–284.
  37. Wolk A, Andersson SO, Mantzoros CS, Trichopoulos D, Adami HO: Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet 2000;356:1902–1903.
  38. Maile LA, Holly JM: Insulin-like growth factor binding protein (IGFBP) proteolysis: Occurrence, identification, role and regulation. Growth Horm IGF Res 1999;9:85–95.
  39. Butler AA, Blakesley VA, Poulaki V, Tsokos M, Wood TL, Le Roith D, Pouliki V: Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res 1998;58:3021–3027.
  40. Werner H, Le Roith D: The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997;8:71–92.
  41. Baserga R: The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1–6.
  42. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59–72.
  43. Seely BL, Reichart DR, Staubs PA, Jhun BH, Hsu D, Maegawa H, Milarski KL, Saltiel AR, Olefsky JM: Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein. J Biol Chem 1995;270:19151–19157.
  44. Petley T, Graff K, Jiang W, Yang H, Florini J: Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res 1999;31:70–76.
  45. Rozengurt E: Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Cancer Surv 1995;24:81–96.
  46. Nolan CM, Kyle JW, Watanabe H, Sly WS: Binding of insulin-like growth factor II (IGF-II) by human cation-independent mannose 6-phosphate receptor/IGF-II receptor expressed in receptor-deficient mouse L cells. Cell Regul 1990;1:197–213.
  47. Dennis PA, Rifkin DB: Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 1991;88:580–584.
  48. Kang JX, Li Y, Leaf A: Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. Proc Natl Acad Sci USA 1997;94:13671–13676.
  49. Wang ZQ, Fung MR, Barlow DP, Wagner EF: Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature 1994;372:464–467.
  50. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C: Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000;97:3455–3460.
  51. Ray BS, Pearson OH: Hypophysectomy in treatment of disseminated breast cancer. Surg Clin North Am 1962;12:419–433.
  52. Colletti RB, Roberts JD, Devlin JT, Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989;49:1882–1884.
  53. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–1396.
  54. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509–517.
  55. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB: Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 1986;46:4613–4619.
  56. Pezzino V, Papa V, Milazzo G, Gliozzo B, Russo P, Scalia PL: Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann NY Acad Sci 1996;784:189–201.
  57. Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 1992;22:31–38.
  58. Lee AV, Darbre P, King RJ: Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol 1994;99:211–220.
  59. Wu HK, Squire JA, Catzavelos CG, Weksberg R: Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun 1997;235:123–129.
  60. Giani C, Pinchera A, Rasmussen A, Fierabracci P, Bonacci R, Campini D, Bevilacqua G, Trock B, Lippman M E, Cullen KJ: Stromal IGF-II messenger RNA in breast cancer: Relationship with progesterone receptor expressed by malignant epithelial cells. J Endocrinol Invest 1998;21:160–165.
  61. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143–163.
  62. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994;269:16433–16442.
  63. Huynh H, Yang X, Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016–1021.
  64. Stewart AJ, Johnson MD, May FE, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265:21172–21178.
  65. Richards RG, Walker MP, Sebastian J, DiAugustine RP: Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1(m/m) mouse. J Biol Chem 1998;273:11962–11969.
  66. Dupont J, Karas M, Le Roith D: The potentiation of estrogen on IGF-I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000;275:35893–35901.
  67. Hebert E, Herbelin C, Bougnoux P: Analysis of the IGF-II receptor gene copy number in breast carcinoma. Br J Cancer 1994;69:120–124.
  68. Papa V, Constantino A, Belfiore A: Insulin receptor: What role in breast cancer? Trends Endocrinol Metab 1997;8:306–312.
  69. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A: Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5:1935–1944.
  70. Guvakova MA, Surmacz E: The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin. Exp Cell Res 1999;251:244–255.
  71. Pratt SE, Pollak MN: Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993;53:5193–5198.
  72. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM: Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J Cell Biochem 1999;75:652–664.
  73. Oh Y, Muller HL, Lamson G, Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993;268:14964–14971.
  74. Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M, Papas T, Seth A: Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998;16:2459–2467.

    External Resources

  75. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511–2519.
  76. Figueroa JA, Lee AV, Jackson JG, Yee D: Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 1995;80:3476–3482.
  77. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53:1102–1106.
  78. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR: Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774–3782.
  79. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115–1118.
  80. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90:911–915.
  81. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563–566.
  82. Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S, Fujita-Yamaguchi Y: Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998;291:469–479.
  83. Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB: Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1995;1:1471–1478.
  84. Iwamura M, Sluss PM, Casamento JB, Cockett AT: Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243–252.
  85. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP: Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271–1279.
  86. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL: Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 1997;138:1728–1735.
  87. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474–5478.
  88. Huynh H, Seyam RM, Brock GB: Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 1998;58:215–218.
  89. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996;81:411–420.
  90. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J Clin Endocrinol Metab 1996;81:3783–3792.
  91. Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res 1999;59:2370–2375.
  92. Gregory CW, Kim D, Ye P, D’Ercole AJ, Pretlow TG, Mohler JL, French FS: Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 1999;140:2372–2381.
  93. Drivdahl RH, Loop SM, Andress DL, Ostenson RC: IGF-binding proteins in human prostate tumor cells: Expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 1995;26:72–79.
  94. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229–233.
  95. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181–12188.
  96. Michell NP, Langman MJ, Eggo MC: Insulin-like growth factors and their binding proteins in human colonocytes: Preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 1997;76:60–66.
  97. Jehle PM, Fussgaenger RD, Blum WF, Angelus NK, Hoeflich A, Wolf E, Jungwirth RJ: Differential autocrine regulation of intestine epithelial cell proliferation and differentiation by insulin-like growth factor (IGF) system components. Horm Metab Res 1999;31:97–102.
  98. Remacle-Bonnet M, Garrouste F, el Atiq F, Marvaldi J, Pommier G: Cell polarity of the insulin-like growth factor system in human intestinal epithelial cells. Unique apical sorting of insulin-like growth factor binding protein-6 in differentiated human colon cancer cells. J Clin Invest 1995;96:192–200.
  99. Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier GJ: Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000;60:2007–2017.
  100. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998;58:4008–4014.
  101. Singh P, Rubin N: Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 1993;105:1218–1237.
  102. Remacle-Bonnet MM, Culouscou JM, Garrouste FL, Rabenandrasana C, Marvaldi JL, Pommier GJ: Expression of type I, but not type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line. J Clin Endocrinol Metab 1992;75:609–616.
  103. Guo YS, Narayan S, Yallampalli C, Singh P: Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology 1992;102:1101–1108.
  104. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999;30:1128–1133.
  105. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M: Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987;38:223–230.
  106. Singh P, Dai B, Yallampalli C, Xu Z: Expression of IGF-II and IGF-binding proteins by colon cancer cells in relation to growth response to IGFs. Am J Physiol 1994;267:G608–G617.
  107. Culouscou JM, Shoyab M: Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res 1991;51:2813–2819.
  108. Kim SO, Park JG, Lee YI: Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: Implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 1996;56:3831–3836.
  109. Lee YI, Lee S, Lee Y, Bong YS, Hyun SW, Yoo YD, Kim SJ, Kim YW, Poo HR: The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4. Oncogene 1998;16:2367–2380.

    External Resources

  110. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K: Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Dig Dis Sci 1996;41:208–215.
  111. Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, Le Roith D, Levy J, Sharoni Y: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 1996;137:1089–1095.
  112. Frankel S, Gunnell DJ, Peters TJ, Maynard M, Davey Smith G: Childhood energy intake and adult mortality from cancer: The Boyd Orr Cohort Study. BMJ 1998;316:499–504.
  113. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997;57:4667–4672.
  114. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730–2734.
  115. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS: Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000;18:847–853
  116. Ho PJ, Baxter RC: Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997;46:333–342.
  117. Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Diamandis EP: Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001;57:471–475.
  118. Khosravi J, Diamandi A, Mistry J, Scorilas A: Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001;86:694–699.
  119. Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, Hart AA: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62:266–270.
  120. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS: Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998;9:570–573.
  121. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589–1593.
  122. Favoni RE, de Cupis A, Perrotta A, Sforzini S, Amoroso D, Pensa F, Miglietta L: Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: Mutual relationship and possible correlations with patients’ hormonal status. J Cancer Res Clin Oncol 1995;121:674–682.
  123. Kaulsay KK, Ng EH, Ji CY, Ho GH, Aw TC, Lee KO: Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Eur J Endocrinol 1999;140:164–168.
  124. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620–625.
  125. Renehan AG, Jones J, Potten CS, Shalet SM, O’Dwyer ST: Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344–1350.
  126. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O’Dwyer ST: High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 2001;88:107–113.
  127. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, Bell GI, Shows TB: Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986;46:6169–6173.
  128. Petridou E, Dessypris N, Spanos E, Mantzoros C, Skalkidou A, Kalmanti M, Koliouskas D, Kosmidis H, Panagiotou JP, Piperopoulou F, Tzortzatou F, Trichopoulos D: Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. Int J Cancer 1999;80:494–496.
  129. Karasik A, Menczer J, Pariente C, Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271–276.
  130. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997;82:2308–2313.
  131. Evans JD, Eggo MC, Donovan IA, Bramhall SR, Neoptolemos JP: Serum levels of insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not elevated in pancreatic cancer. Int J Pancreatol 1997;22:95–100.
  132. Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS: Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery. J Korean Med Sci 1997;12:32–39.
  133. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, Mantzoros C, Trichopoulos D: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000;87:118–121.
  134. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999;91:151–156.
  135. Lee DY, Kim SJ, Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999;14:401–404.
  136. Mazzoccoli G, Giuliani A, Bianco G, De Cata A, Balzanelli M, Carella AM, La Viola M, Tarquini R: Decreased serum levels of insulin-like growth factor (IGF)-I in patients with lung cancer: Temporal relationship with growth hormone (GH) levels. Anticancer Res 1999;19:1397–1399.
  137. Rutanen EM, Stenman S, Blum W, Karkkainen T, Lehtovirta P, Stenman UH: Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: Comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab 1993;77:199–204.
  138. Ayabe T, Tsutsumi O, Sakai H, Yoshikawa H, Yano T, Kurimoto F, Taketani Y: Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997;44:419–424.
  139. Cohen SM, Ellwein LB: Cell proliferation in carcinogenesis. Science 1990;249:1007–1011.
  140. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, Le Roith D: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96:7324–7329.
  141. O’Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, Woodhull J, Talbot DC, Schally AV, Harris AL: Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999;79:1413–1418.
  142. Csernus VJ, Schally AV, Kiaris H, Armatis P: Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 1999;96:3098–3103.
  143. Pollak M: The potential role of somatostatin analogues in breast cancer treatment. Yale J Biol Med 1997;70:535–539.
  144. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.
  145. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609–1618.
  146. Baserga R: Controlling IGF-receptor function: A possible strategy for tumor therapy. Trends Biotechnol 1996;14:150–152.
  147. Konety BR, Johnson CS, Trump DL, Getzenberg RH: Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol 1999;17:77–84.
  148. Miller WH Jr: The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998;83:1471–1482.
  149. Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, Braun HJ, Burghouts JT, van der Linden GH, Klijn JG: Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: A randomized study with long-term follow-up. Br J Cancer 1998;77:115–122.
  150. Ritzen EM: Does growth hormone increase the risk of malignancies? Horm Res 1993;39:99–101.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50